It functions as a reducing agent to donate electrons to neutralize ROS and free radicals, thereby preventing oxidative damage to cellular structures such as lipids, proteins, and DNA
Adults with overweight or obesity newly prescribed liraglutide (Victoza/Saxenda, Novo Nordisk), subcutaneous semaglutide (Ozempic/Wegovy, Novo Nordisk) or tirzepatide (Mounjaro/Zepbound, Eli Lilly) from 2018 to 2023 were included
Evidence Summary Large GLP-1 trials did not identify iron deficiency as a primary outcome
Monotherapy data suggests cagrilintide is effective at 2.4 mg weekly and retatrutide at 8-12 mg weekly, but these doses cannot simply be combined without understanding potential interactions
Ensure adequate fluid intakeat least 1.52 litres dailyas both GLP-1 medications and laxatives require sufficient hydration to work effectively
Most current users inject AOD-9604 rather than taking it orally, so the trial data may underestimate what injectable protocols achieve